- Home
- CRMD vs PHK Comparison
CRMD vs PHK Comparison
Compare CRMD & PHK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRMD
- PHK
- Stock Information
- Founded
- CRMD 2006
- PHK 2003
- Country
- CRMD United States
- PHK United States
- Employees
- CRMD N/A
- PHK N/A
- Industry
- CRMD Biotechnology: Pharmaceutical Preparations
- PHK Finance/Investors Services
- Sector
- CRMD Health Care
- PHK Finance
- Exchange
- CRMD Nasdaq
- PHK Nasdaq
- Market Cap
- CRMD 645.0M
- PHK 765.2M
- IPO Year
- CRMD 2010
- PHK N/A
- Fundamental
- Price
- CRMD $6.30
- PHK $4.88
- Analyst Decision
- CRMD Strong Buy
- PHK
- Analyst Count
- CRMD 7
- PHK 0
- Target Price
- CRMD $15.14
- PHK N/A
- AVG Volume (30 Days)
- CRMD 2.1M
- PHK 491.5K
- Earning Date
- CRMD 05-08-2025
- PHK 01-01-0001
- Dividend Yield
- CRMD N/A
- PHK 12.61%
- EPS Growth
- CRMD N/A
- PHK N/A
- EPS
- CRMD N/A
- PHK N/A
- Revenue
- CRMD $43,472,170.00
- PHK N/A
- Revenue This Year
- CRMD $192.92
- PHK N/A
- Revenue Next Year
- CRMD $56.23
- PHK N/A
- P/E Ratio
- CRMD N/A
- PHK N/A
- Revenue Growth
- CRMD N/A
- PHK N/A
- 52 Week Low
- CRMD $3.61
- PHK $4.13
- 52 Week High
- CRMD $13.85
- PHK $5.15
- Technical
- Relative Strength Index (RSI)
- CRMD 25.68
- PHK 45.66
- Support Level
- CRMD $6.92
- PHK $4.83
- Resistance Level
- CRMD $11.32
- PHK $4.90
- Average True Range (ATR)
- CRMD 0.62
- PHK 0.03
- MACD
- CRMD -0.44
- PHK 0.00
- Stochastic Oscillator
- CRMD 7.72
- PHK 71.43
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.
About PHK Pimco High Income Fund
PIMCO High Income Fund is a closed-end management investment company. The company's primary investment objective is to seek high current income. Its secondary objective is to seek capital appreciation.